§ 1.136(a), and any fees required therefor (including fees for net addition of claims) are hereby authorized to be charged to our Deposit Account No. 19-0036.

Amendments

Please amend the application as follows:

In the Claims:

Please add the following new claims:

- 47. (New) An isolated protein comprising amino acids 36 to 212 of SEQ ID NO:2.
- 48. (New) The isolated protein of claim 47 wherein said isolated protein comprises amino acids 36 to 428 of SEQ ID NO:2.
- 49. (New) The isolated protein of claim 47 wherein said isolated protein comprises amino acids 1 to 428 of SEQ ID NO:2.
- 50. (New) The isolated protein of claim 47, which is produced by a recombinant host cell.
- 51. (New) The isolated protein of claim 47, which comprises a heterologous polypeptide.

53. (New) An isolated protein comprising at least 30 contiguous amino acids of a polypeptide having the amino acid sequence from 1 to 428 of SEQ ID NO:2.

54. (New) The isolated protein of claim 53, which comprises at least 50 contiguous amino acids of a polypeptide having the amino acid sequence from 1 to 428 of SEQ ID NO:2.

55. (New) The isolated protein of claim 53, which comprises at least 30 contiguous amino acids of a polypeptide having the amino acid sequence from 1 to 212 of SEQ ID NO:2.

56. (New) The isolated protein of claim 53, which comprises at least 50 contiguous amino acids of a polypeptide having the amino acid sequence from 1 to 212 of SEQ ID NO:2.

57. (New) The isolated protein of claim 53, which comprises at least 30 contiguous amino acids of a polypeptide having the amino acid sequence from 36 to 428 of SEQ ID NO:2.

58. (New) The isolated protein of claim 53, which comprises at least 50 contiguous

Tot.

amino acids of a polyperitide having the amino acid sequence from 36 to 428 of SEQ ID NO:2.

- 59. (New) The isolated protein of claim 53, which comprises at least 30 contiguous amino acids of a polypeptide having the amino acid sequence from 36 to 212 of SEQ ID NO:2.
- 60. (New) The isolated protein of claim 53, which comprises at least 50 contiguous amino acids of a polypeptide having the amino acid sequence from 36 to 212 of SEQ ID NO:2.
- 61. (New) The isolated protein of claim 53, which is produced by a recombinant host cell.
- 62. (New) The isolated protein of claim 53, which comprises a heterologous polypeptide.
- 63. (New) A composition comprising the isolated protein of claim 53 and a pharmaceutically acceptable carrier.
- 64. (New) An isolated protein comprising an amino acid sequence selected from the group consisting of:
 - (a) amino acids 1 to 22 of SEQ ID NO:2;
 - (b) amino acids 33 to 56 of SEQ ID NO:2;

1) (nt

- (c) amino acids 59 to 82 of SEQ ID NO:2;
- (d) amino acids 95 to 112 of SEQ ID NO:2;
- (e) amino acids 122 to 133 of SEQ ID NO:2;
- (f) amino acids 161 to 177 of SEQ ID NO:2;
- (g) amino acids 179 to 190 of SEQ ID NO:2; and
- (h) amino acids 196 to 205 of SEQ ID NO:2.
- 65. (New) The isolated protein of claim 64, wherein said protein comprises amino acids 1 to 22 of SEQ ID NO:2.
- 66. (New) The isolated protein of claim 64, wherein said protein comprises amino acids 33 to 56 of SEQ ID NO:2,
- 67. (New) The isolated protein of claim 64, wherein said protein comprises amino acids 59 to 82 of SEQ ID NO:2.
- 68. (New) The isolated protein of claim 64, wherein said protein comprises amino acids 95 to 112 of SEQ ID NO:2.
- 69. (NEW) The isolated protein of claim 64, wherein said protein comprises amino acids 122 to 133 of SEQ ID NO:2.
- 70. (New) The isolated protein of claim 64, wherein said protein comprises amino acids

Di

161 to 177 of SEQ ID NO:2.

- 71. (New) The isolated protein of claim 64, wherein said protein comprises amino acids 179 to 190 of SEQ ID NO:2.
- 72. (New) The isolated protein of claim 64, wherein said protein comprises amino acids 196 to 205 of SEQ ID NO:2.
- 73. (New) The isolated protein of claim 64, which is produced by a recombinant host cell.
- 74. (New) The isplated protein of claim 64, which comprises a heterologous polypeptide.
- 75. (New) A composition comprising the isolated protein of claim 64 and a pharmaceutically acceptable carrier.

Ti Ont